trial

Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia

NCTId NCT01246232
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 69 (actual)
Sponsored by Imperial College London
Primary completion 2015-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
69 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2011-09
Primary completion
2015-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Amisulpride

Sponsors

Imperial College LondonLead Sponsor
University of ManchesterCollaborator
University College, LondonCollaborator

Investigators

1
Thomas R Barnes, MDPrincipal Investigator

Sites

3 total
London, United KingdomLondon, United KingdomManchester, United Kingdom

Facts & assertions

4 sourced
Enrollment
69
Phase
PHASE4
Primary Completion Date
2015-03
Status
COMPLETED
relationships
The graph out of here
drug
Amisulpride
drug
lead_sponsor
Imperial College London
company
collaborator
University of Manchester
company
University College, London
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Thomas R Barnes, MD
person